All In Biotech

Drug Trial Radar · NCT01000961

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis

Last checked: Nov 20, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

43

Actual

Start

Jun 2010

Primary completion

Jun 2011

Study completion Aug 2011

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Oct 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cystinosis is an inherited disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate) which must be taken every six hours for the rest of the patient's life to prevent complications of cystinosis. RP103 is a formulation of cysteamine bitartrate that is being studied to see if it may be able to be given less frequently, once every 12 hours, and have similar results to four times a day Cystagon®.

Conditions

  • Cystinosis

Interventions

  • Cystagon® (Cysteamine Bitartrate)Drug

    Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1: Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used

  • Cysteamine Bitartrate Delayed-release Capsules (RP103)Drug

    Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1: Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Steady-state White Blood Cell Cystine Levels of RP103 Compared to Cystagon®Time frame: 4 weeks after the last subject has completed the study

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Stanford University Medical School

    Stanford, California

  • Emory Children's Center

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago (formerly Children's Memorial Hospital)

    Chicago, Illinois

  • Hospices Civils de Lyon

    Lyon, France

  • Villeneuve-Lapeyronie Hospital

    Montpellier, France

  • Necker Hospital

    Paris, France

  • Robert Debre Hospital

    Paris, France

  • Radboud University Nijmegen Medical Center

    Nijmegen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.